FTC Opposes Amgen’s Acquisition of Horizon Therapeutics: Latest Updates and Impact on the Future of Medicine

2023-06-23 12:54:00

(AOF) – Amgen is expected to be slightly lower in pre-market on Wall Street following six US states (California, New York, Illinois, Minnesota, Washington and Wisconsin) joined the action in brought by the FTC (Federal Trade Commission) to prevent the acquisition by Amgen of Horizon Therapeutics for an amount of 27.8 billion dollars, for abuse of dominant position. The takeover was announced in mid-December 2022 and the FTC officially declared its opposition to the transaction in mid-May 2023.

The six-state group filed an amended lawsuit on Thursday, joining the FTC, which last month opposed the deal because it would give Amgen ‘monopoly positions’ over drugs used in the treatment thyroid disease of the eye and chronic refractory gout.

Loading…

“Amgen’s proposed acquisition of Horizon is dangerous for the future of medicine, for innovation and research, and most importantly, for patients who need medicines that often save lives,” Rob said. Bonta, Attorney General of California.

© AOF Legal disclaimer

The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

1687526163
#Amgen #expected #decline #states #attack #Horizon #Therapeutics #takeover